Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more
Enlivex Therapeutics Ltd (ENLV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.131x
Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) has a cash flow conversion efficiency ratio of -0.131x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.30 Million) by net assets ($17.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enlivex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Enlivex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Enlivex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enlivex Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sahamit Machinery Public Company Limited
BK:SMIT
|
0.036x |
|
SMT SCHARF AG NA O.N.
F:S4AA
|
0.073x |
|
Seco/Warwick SA
WAR:SWG
|
-0.098x |
|
Thai Plaspac Public Company Limited
BK:TPAC
|
0.116x |
|
ENOGIA EO -10
F:7BZ
|
N/A |
|
OpenLocker Holdings Inc
PINK:OLKR
|
2.290x |
|
Allakos Inc
NASDAQ:ALLK
|
-0.511x |
|
ANGLER GAMING PLC EO -01
F:0QM
|
N/A |
Annual Cash Flow Conversion Efficiency for Enlivex Therapeutics Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Enlivex Therapeutics Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $23.59 Million | $-13.01 Million | -0.551x | +29.47% |
| 2023-12-31 | $30.08 Million | $-23.52 Million | -0.782x | -85.55% |
| 2022-12-31 | $56.84 Million | $-23.95 Million | -0.421x | -104.29% |
| 2021-12-31 | $85.04 Million | $-17.54 Million | -0.206x | +33.49% |
| 2020-12-31 | $35.49 Million | $-11.01 Million | -0.310x | +50.30% |
| 2019-12-31 | $11.28 Million | $-7.04 Million | -0.624x | -91.63% |
| 2018-12-31 | $9.71 Million | $-3.16 Million | -0.326x | +83.79% |
| 2017-12-31 | $3.16 Million | $-6.35 Million | -2.009x | -12.84% |
| 2016-12-31 | $8.70 Million | $-15.49 Million | -1.780x | -140.94% |
| 2015-12-31 | $17.93 Million | $-13.25 Million | -0.739x | -414.03% |
| 2014-12-31 | $30.67 Million | $-4.41 Million | -0.144x | +7.69% |
| 2013-12-31 | $5.55 Million | $-865.00K | -0.156x | +92.16% |
| 2012-12-31 | $75.00K | $-149.00K | -1.987x | -- |